Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
An immunohistochemical characterization of basal cell carcinoma in patients below 40 years of age.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Waller Vincent, Boeschen Myriam, Lingscheidt Thomas, Stiller Mathias, Eickenscheidt Lena, Wilhelm Thomas, Grunewald Sonja, Ziemer Mirjana, Simon Jan-Christoph, Bläker Hendrik, von Laffert Maximilian
Аннотация
BACKGROUND: Basal cell carcinoma (BCC) is the most common form of skin cancer, mainly occurring in the elderly. Studies on BCC patients under the age of 40 (early-onset BCC) are scarce.
PATIENTS AND METHODS: 52 BCCs (48 patients, median age: 35 years) were investigated using immunohistochemistry, focusing on the cell cycle, immunogenicity, and HER2 expression. We used PCR to test for Human Papilloma Virus (HPV) and chromogenic in-situ hybridization for HER2 subclassification.
RESULTS: 69% of cases were classified as non-aggressive subtypes, and 31% as aggressive. Changes in p16 and/or p53 were observed in 44% of cases. No HPV-DNA was detected. Overexpression of p16 was associated with an aggressive growth pattern, whereas p53 changes were independent of the growth pattern. Aggressive subtypes and p16-positivity correlated with higher expression levels of cyclin E1 and Ki-67, as well as a stronger B-cell response. Similar findings were observed in p53-altered basal cell carcinomas with respect to Ki-67 expression and B-lymphocyte infiltration; however, cyclin E1 expression was reduced in this subgroup. 71% of tumors belonged to the HER2-low group, which was associated with higher expression levels of cyclin E1 and Ki-67 and a more pronounced immunogenic response.
CONCLUSIONS: This is the largest immunohistochemical characterization of early-onset BCC to date. The classification into non-aggressive and aggressive subtypes appears appropriate, as applied in the elderly. Further sub-classification based on p16, p53, and HER2 may reflect disrupted cell cycle mechanisms combined with an immunogenic response.
PATIENTS AND METHODS: 52 BCCs (48 patients, median age: 35 years) were investigated using immunohistochemistry, focusing on the cell cycle, immunogenicity, and HER2 expression. We used PCR to test for Human Papilloma Virus (HPV) and chromogenic in-situ hybridization for HER2 subclassification.
RESULTS: 69% of cases were classified as non-aggressive subtypes, and 31% as aggressive. Changes in p16 and/or p53 were observed in 44% of cases. No HPV-DNA was detected. Overexpression of p16 was associated with an aggressive growth pattern, whereas p53 changes were independent of the growth pattern. Aggressive subtypes and p16-positivity correlated with higher expression levels of cyclin E1 and Ki-67, as well as a stronger B-cell response. Similar findings were observed in p53-altered basal cell carcinomas with respect to Ki-67 expression and B-lymphocyte infiltration; however, cyclin E1 expression was reduced in this subgroup. 71% of tumors belonged to the HER2-low group, which was associated with higher expression levels of cyclin E1 and Ki-67 and a more pronounced immunogenic response.
CONCLUSIONS: This is the largest immunohistochemical characterization of early-onset BCC to date. The classification into non-aggressive and aggressive subtypes appears appropriate, as applied in the elderly. Further sub-classification based on p16, p53, and HER2 may reflect disrupted cell cycle mechanisms combined with an immunogenic response.